ixabepilone + cisplatin

**Ixabepilone + cisplatin** is an investigational combination regimen composed of ixabepilone, a semisynthetic epothilone B analog microtubule inhibitor, and cisplatin, a platinum-based chemotherapy agent that forms DNA crosslinks. Ixabepilone binds directly to beta-tubulin subunits of microtubules, stabilizing them and interfering with mitosis, whereas cisplatin induces apoptosis by covalently binding to DNA, thereby inhibiting DNA synthesis and function. The combination is being researched primarily for the treatment of non-small cell lung cancer and potentially other solid tumors, aiming to exploit complementary mechanisms to combat chemoresistance in advanced malignancies[4].